Newsfeeds - Spark Newswire

4 minute read

Altimmune Announces Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers; Weight Loss Of 5.4% Achieved At 6 Weeks With 1.8 mg Once Weekly Dose

June 16, 7:01 AM

Weight loss of 5.4% achieved at 6 weeks of treatment with 1.8 mg once weekly dose, surpassing the 2% pre-established treatment target Ascending multi-dose regimen well-tolerated without

ALT

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 2, 2021

By Benzinga Insights

June 2, 10:09 AM

ALT

4 minute read

Uncategorized

52 Biggest Movers From Yesterday

By Lisa Levin

May 25, 4:56 AM

Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive immuno-oncology RNA therapy for the treatment of multiple cancers.

ALT